SRA downsizes with sale of research group
SRA Global Clinical Development group sold to biopharmaceutical Aptiv Solutions
- By David Hubler
- Oct 03, 2011
SRA International Inc. has sold its contract research organization, SRA Global Clinical Development LLC, to biopharmaceutical Aptiv Solutions Inc., SRA announced Oct. 3.
Financial terms of the transaction, which is effective immediately, were not disclosed.
“We believe the GCD business, as a part of Aptiv Solutions, has greater opportunity to pursue a wider range of initiatives that align with its mission,” SRA President and CEO Bill Ballhaus said in the announcement.
SRA announced earlier this year that it had decided to divest SRA Global Clinical Development and its wholly owned subsidiaries.
Aptiv Solutions, of Reston, Va., is a global biopharmaceutical and medical device development services company focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes facing companies developing products in the pharmaceutical, biotech and medical device market, the announcement explained.
SRA International Inc., of Fairfax, Va., ranks No. 29 on Washington Technology’s 2011 Top 100 list of the largest federal government contractors.
David Hubler is the former print managing editor for GCN and senior editor for Washington Technology. He is freelance writer living in Annandale, Va.